高临床概率肺栓塞患者D-二聚体检测失败率:三项欧洲研究的辅助分析
该研究为三项欧洲研究(PROPER、MODIGLIANI、TRYSPEED)的事后分析,纳入651例高临床概率肺栓塞且行D-二聚体检测的患者。D-二聚体低于年龄调整阈值(<50岁<500 ng/mL,>50岁年龄×10 ng/mL)排除肺栓塞,主要终点为阴性患者即时或3个月随访的血栓栓塞事件。70例D-二聚体低于阈值者随访后无肺栓塞,失败率0.0%(95%CI 0.0%-6.5%);贝叶斯分析可信区间0.0%-4.1%,失败率低于2%的后验概率76.2%。作者认为该策略安全,但主要终点置信区间宽,无法定论。
要点
- 高临床概率肺栓塞患者中,D-二聚体低于年龄调整阈值(<50岁<500 ng/mL,>50岁年龄×10 ng/mL)排除肺栓塞,70例中无肺栓塞,失败率0.0%(95%CI 0.0%-6.5%)。
- 贝叶斯分析显示失败率低于2%的后验概率为76.2%,可信区间0.0%-4.1%。
- 纳入的651例患者中肺栓塞患病率为31.3%,中位年龄68岁,女性占60%。
- 作者认为基于年龄调整阈值D-二聚体排除高临床概率肺栓塞是安全的,但主要终点置信区间宽,无法定论。
适用人群与场景
- 三项欧洲研究(PROPER、MODIGLIANI、TRYSPEED)中,根据Wells或修订版日内瓦评分评估为高临床概率肺栓塞且行D-二聚体检测的患者。
诊断标准与关键阈值
- 高临床概率肺栓塞:根据Wells或修订版日内瓦评分。
- D-二聚体年龄调整阈值:年龄小于50岁者<500 ng/mL,年龄大于50岁者年龄×10 ng/mL。
- D-二聚体低于年龄调整阈值可排除肺栓塞。
研究设计与关键结果
- 研究类型:三项欧洲研究(PROPER、MODIGLIANI、TRYSPEED)的事后分析。
- 样本量:从12,300例中纳入651例,中位年龄68岁,女性占60%。
- 肺栓塞患病率为31.3%。
- 70例D-二聚体低于年龄调整阈值,随访后无肺栓塞,失败率0.0%(95%CI 0.0%-6.5%)。
- 贝叶斯分析:可信区间0.0%-4.1%,失败率低于2%的后验概率为76.2%。
证据类型、等级与局限
- 证据类型:三项欧洲研究(PROPER、MODIGLIANI、TRYSPEED)的事后分析。
- 局限:主要终点置信区间宽,无法定论。
对床旁实践的改变
- 作者认为,在高临床概率肺栓塞患者中,基于D-二聚体低于年龄调整阈值排除肺栓塞是安全的,无漏诊肺栓塞。
- 但主要终点置信区间宽,无法定论。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients with a high clinical probability of pulmonary embolism (PE), the high prevalence can lower the D-dimer negative predictive value and increase the risk of diagnostic failure. It is therefore recommended that these high-risk patients should undergo chest imaging without D-dimer testing although no evidence supports this recommendation.
OBJECTIVE: The objective was to evaluate the safety of ruling out PE based on D-dimer testing among patients with a high clinical probability of PE.
METHODS: This was a post hoc analysis of three European studies (PROPER, MODIGLIANI, and TRYSPEED). Patients were included if they presented a high clinical probability of PE (according to either the Wells or the revised Geneva score) and underwent D-dimer testing. The D-dimer-based strategy ruled out PE if the D-dimer level was below the age-adjusted threshold (i.e., <500 ng/mL in patients aged less than 50 and age × 10 ng/mL in patients older than 50). The primary endpoint was a thromboembolic event in patients with negative D-dimer either at index visit or at 3-month follow-up. A Bayesian approach estimated the probability that the failure rate of the D-dimer-based strategy was below 2% given observed data.
RESULTS: Among the 12,300 patients included in the PROPER, MODIGLIANI, and TRYSPEED studies, 651 patients (median age 68 years, 60% female) had D-dimer testing and a high clinical probability of PE and were included in the study. PE prevalence was 31.3%. Seventy patients had D-dimer levels under the age-adjusted threshold, and none of them had a PE after follow-up (failure rate 0.0% [95% CI 0.0%-6.5%]). Bayesian analysis reported a credible interval of 0.0%-4.1%, with a 76.2% posterior probability of a failure rate below 2%.
CONCLUSIONS: In this study, ruling out PE in high-risk patients based on D-dimer below the age-adjusted threshold was safe, with no missed PE. However, the large CI of the primary endpoint precludes a definitive conclusion.
参考来源
- Bannelier H, Kapfer T, Roussel M, et al. Failure rate of D-dimer testing in patients with high clinical probability of pulmonary embolism: Ancillary analysis of three European studies. Acad Emerg Med. 2024. PMID: 39487597. doi:10.1111/acem.15032
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。